:660-6.
134. Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V,
Dâ€™Ambrosio A, et al. Short-term, high-dose atorvastatin
pretreatment to prevent contrast-induced nephropathy in
patients with acute coronary syndromes undergoing
percutaneous coronary intervention (from the ARMYDACIN [atorvastatin for reduction of myocardial damage
during angioplasty-contrast-induced nephropathy] trial.
Am J Cardiol 2011;108:1-7.
135. Leoncini M, Toso A, Maioli M, Tropeano F, Badia T, Villani S,
et al. Early high-dose rosuvastatin and cardioprotection in
the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome
(PRATO-ACS) study. Am Heart J 2014;168:792-7.

58

Chaikof et al

Journal of Vascular Surgery
January 2018

136. Subramaniam RM, Suarez-Cuervo C, Wilson RF, Turban S,
Zhang A, Sherrod C, et al. Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and meta-analysis. Ann Intern Med 2016;164:406-16.
137. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R,
Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491-9.
138. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for
contrast-induced nephropathy. JAMA 2006;295:2765-79.
139. Pannu N, Tonelli M. Strategies to reduce the risk of contrast
nephropathy: an evidence-based approach. Curr Opin
Nephrol Hypertens 2006;15:28